Schizophrenia Case Study Cynthia

Cynthia is a 65 year old African American female diagnosed with type 2 diabetes mellitus, diabetic peripheral neuropathy, hypertension, kidney disease, hyperlipidemia and hypothyroidism.

Assessment and plan of treatment for Cynthia

Diabetes Mellitus: Will treat with Glipizide 5 mg po daily

Diabetic Peripheral Neuropathy: Will treat with Duloxetine 60mg po daily.

Hypertension: Will treat with Lisinopril 10mg po daily.

Kidney disease: Will treat with Lisinopril 10mg po daily

Hyperlipidemia: Will treat with Atorvastatin 20mg po daily.

Hypothyroidism: Will treat with Levothyroxine 50mg po daily

Glipizide: Glipizide is an oral rapid acting antidiabetic drug from the class of sulfonylurea. It is a second generation of sulfonylurea that undergoes enterohepatic circulation. The efficacy of the glipizide can be observed by monitoring the glycemic control. However, it is important to observe the toxicity of glipizide as well. Sulfonylureas can decrease the serum glucagon and potentiate

Lisinopril can cause symptomatic hypotension, and sometimes it can be complicated by oliguria, progressive azotemia, or acute renal failure. Patient at risk for hypotension should be careful about this medicine and should be started under the close medical supervision and should be followed closely during the first two week of treatment and whenever there is a dose increase. During the treatment, potassium level should be monitored as it can cause hyperkalemia. Patient can develop hepatic failure, therefore patient who develop jaundice or marked hepatic enzyme elevations should immediately discontinue the medicine. Lisinopril can cause angioedema and patient need to be educated about this. Impaired renal function is possible, therefore patient taking Lisinopril need to monitor their renal function periodically. The effectiveness of the treatment can be monitored thorough the monitoring of the blood pressure (Kaufman,